MesoblastMESO
Market Cap: $739M
About: Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Employees: 73
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
67% more capital invested
Capital invested by funds: $5.83M [Q1] → $9.74M (+$3.91M) [Q2]
46% more funds holding
Funds holding: 26 [Q1] → 38 (+12) [Q2]
38% more call options, than puts
Call options by funds: $3.22M | Put options by funds: $2.34M
0.02% more ownership
Funds ownership: 0.1% [Q1] → 0.13% (+0.02%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Piper Sandler Edward Tenthoff 38% 1-year accuracy 13 / 34 met price target | 70%upside $11 | Overweight Upgraded | 23 Jul 2024 |
Financial journalist opinion
Based on 3 articles about MESO published over the past 30 days